司美格鲁肽治疗氯氮平相关肥胖的精神分裂症患者:COaST 2期随机对照试验
因研究药物不可获得,招募在 31 例时提前中止;
要点
- 氯氮平及去甲氯氮平浓度、PANSS 评分在两组间无差异。
- 司美格鲁肽耐受良好,无与治疗相关的严重不良事件。
核心结论
- 在这项小样本试验中,司美格鲁肽较安慰剂带来显著更大的体重下降,且未影响精神病性症状或氯氮平浓度,在该人群中表现安全且耐受良好。
研究设计与样本
- COaST 为澳大利亚随机、安慰剂对照、多中心试验,不依赖制药业资助,方法纳入有亲身经历者参与。
- 纳入 18-64 岁、符合精神分裂症或分裂情感障碍标准、已处方氯氮平 18 周或以上、BMI 至少 26 kg/m2、且前 3 个月体重增减小于 5% 的成人。
- 166 例筛查后 135 例被排除,31 例随机分配至司美格鲁肽组(n=15)或对照组(n=16);因研究药物不可获得,招募在达到计划 80 例前于 2024 年 6 月中止。
- 主要结局为 36 周时体重变化百分比,采用重复测量混合模型分析;次要指标包括氯氮平及去甲氯氮平浓度和 PANSS 评分。
主要发现
- 氯氮平或去甲氯氮平浓度未见差异,PANSS 评分也未见差异。
- 司美格鲁肽耐受良好,无被认为与治疗相关的严重不良事件,便秘发生率低。
关键数值与推荐
- 纳入 BMI 至少 26 kg/m2,且前 3 个月体重增减小于 5%。
- 氯氮平处方时长要求 18 周或以上。
临床怎么用
- 对于服用氯氮平且合并肥胖的精神分裂症或分裂情感障碍成人,司美格鲁肽可作为减重选项,且未观察到精神病性症状或氯氮平浓度受影响。
- 使用司美格鲁肽期间仍需常规监测氯氮平浓度和精神病性症状,尽管本试验未发现差异。
- 本试验样本量小且提前中止,结果需在更大规模确证性试验中验证后再广泛推广。
局限性
- 因研究药物不可获得,招募在 31 例时提前中止,未达到计划 80 例,样本量小。
- 试验仅在澳大利亚 6 个中心开展,84% 参与者为白人,外推性受限。
- 随访至 36 周,缺乏更长期体重维持和代谢结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with schizophrenia have a 16-20-year reduction in life expectancy, primarily due to cardiometabolic disease. Clozapine, the most efficacious antipsychotic for treatment-resistant schizophrenia, is associated with weight gain and metabolic dysfunction. Glucagon-like peptide-1 receptor agonists, including semaglutide, contribute to substantial weight loss in the general population, but their effect and safety profile in people with schizophrenia remain unknown. We evaluated the efficacy and safety of semaglutide for weight reduction in individuals with schizophrenia who were prescribed clozapine. METHODS: COaST was an Australian randomised, placebo-controlled, multi-site trial, independent of pharmaceutical industry support, with methods informed by people with lived experience. Adults (aged 18-64 years) across six sites were randomly assigned (1:1) to once weekly subcutaneous semaglutide titrated to 2·0 mg or placebo for 36 weeks. Participants were included if they fulfilled criteria for schizophrenia or schizoaffective disorder, were prescribed clozapine for 18 weeks or more, had a BMI of at least 26 kg/m2, and had less than 5% bodyweight increase or loss in the previous 3 months. The primary outcome was percentage body weight change, analysed using a mixed model for repeated measures, at 36 weeks post-baseline assessment. All investigators and participants were masked to medication allocation. Secondary measures included clozapine and norclozapine concentrations and psychosis symptoms as measured by the Positive and Negative Syndrome Scale (PANSS). The protocol was prospectively registered with the Australia New Zealand Clinical Trials Registry (ACTRN12621001539820; recruitment finished, pending follow-up assessments). FINDINGS: 166 individuals were screened for eligibility, 135 were excluded, and the remaining 31 were randomly assigned to either the semaglutide group (n=15) or the control group (n=16). 21 males and ten females were included in the study, with a mean age of 38·9 years (range 21-58). All participants assigned to each group were included in the analysis of the primary outcome. 84% of participants were White, 7% were from the Indian Subcontinent, 3% were Asian (not including from the Indian Subcontinent), 3% were Australian Aboriginal or Torres Strait Islanders, and 3% were New Zealand Māori or Pacific Islanders. Recruitment commenced on Aug 30, 2022 and was suspended in June, 2024 before achieving the intended number of 80 participants due to non-availability of the investigational product. At week 36, semaglutide yielded a 13·88% (SE 0·90) body weight reduction compared with 0·42% (SE 0·93) for placebo (between-group difference: -13·46%; p<0·0001). No differences were observed in clozapine or norclozapine concentrations or PANSS scores. Semaglutide was well tolerated, with no serious adverse events that were deemed to be related to the treatment, and low rates of constipation. INTERPRETATION: Semaglutide led to significantly greater weight loss than placebo in this small trial without affecting psychotic symptoms or clozapine concentrations. Semaglutide appears to be safe and well tolerated in this population. These encouraging findings highlight the need for larger confirmatory trials. FUNDING: National Health and Medical Research Council, Qld Advancing Clinical Research Fellowship, and Metro South Health Research Support Scheme Program.
引用
- Siskind D, Baker A, Arnautovska U, et al. Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia. Lancet Psychiatry. 2025. PMID: 40506208. doi:10.1016/S2215-0366(25)00129-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。